Camel Milk Casein Nanoparticles for Targeted Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges in differentiating between malignant and healthy cells, leading to severe systemic toxicity, and existing nanoparticle technologies struggle with controlling particle size and stability, especially when using natural polymers.
Innovation Solution
Development of camel milk-derived lactoferrin and casein nanoparticles, combined with glycosaminoglycans, that form stable nanostructures with controlled size ranges, capable of encapsulating active substances and targeting specific markers, thereby providing a safer and more effective therapeutic agent.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If synthetic polymers are used for nanoparticle carrier, then storage stability and in-vivo particle stability are improved, but toxicity increases compared to natural substances
Solution Approach 1:
The patent changes the material parameter from synthetic polymer to natural polymer (casein), maintaining stability while reducing toxicity. The casein nanoparticle formulation achieves both storage stability and reduced harmful effects by utilizing biocompatible natural materials with appropriate molecular weight and structural properties.
2Object-affected harmful factors
If natural polymers are used for nanoparticle carrier, then safety is improved compared to synthetic polymers, but particle size control becomes difficult
Solution Approach 1:
The patent controls particle size by adjusting casein concentration, pH, ionic strength, and temperature parameters during nanoparticle formation. These parameter changes enable precise control of nanoparticle size distribution while maintaining the safety advantages of natural polymers.
Solution Approach 2:
The patent employs feedback control during nanoparticle preparation by monitoring particle size and adjusting formulation parameters accordingly. This ensures consistent particle size control through iterative optimization of casein nanoparticle formation conditions.
3Productivity
If conventional cancer treatments are applied, then cancer cells are targeted, but differentiation between malignant and healthy cells is lost leading to systemic toxicity
Solution Approach 1:
The patent applies local quality by functionalizing casein nanoparticle surfaces with specific ligands that recognize cancer cell markers. This enables the nanoparticle to deliver therapeutic agents selectively to cancer cells while leaving healthy cells unaffected, achieving localized action with reduced systemic toxicity.
Solution Approach 2:
The casein nanoparticle acts as an intermediary carrier that bridges the gap between therapeutic agents and cancer cells. The nanoparticle surface can be modified with targeting moieties that mediate specific recognition of cancer cells, enabling selective drug delivery without direct contact between toxic agents and healthy tissues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles demonstrate enhanced stability and controlled size distribution, allowing for targeted drug delivery and reduced toxicity, effectively suppressing cancer and viral proliferation while minimizing harm to healthy cells.
Implementation Method 1
camel derived Lactoferrin and/or casein nanoparticle... having an average particle size between 50-200 nm by mixing Lactoferrin and/or casein into basic aqueous medium between pH 8.5-10.5; adding at least one type of active substance... to the basic solution; and then mixing this solution into an acidic aqueous medium
Implementation Method 2
camel derived Lactoferrin (LF) and/or Casein (CA) nanoparticle... comprising camel derived Lactoferrin and/or Casein and/or Low-molecular-weight chitosan and/or a combination thereof... camel derived Lactoferrin and/or casein are protein insoluble in water contained in camel milk
Data Source
AI summary
The present invention provides a composition, a dairy product, and a method for treating a disorder in a subject. The composition includes (i) polymeric nanoparticles and (ii) camel derived glycosaminoglycans (GAG)s ionic complex encapsulated into the nanoparticles, at least one active ingredient encapsulated into the nanoparticles, or combinations thereof. The nanoparticles are lactoferrin nanoparticles including camel derived lactoferrin, casein nanoparticles including camel derived casein, or combinations thereof. The dairy product includes ice cream or frozen yogurt, wherein the ice cream or frozen yogurt includes the composition and is derived from camel milk or other species of milk. The method for treating a disorder in a subject includes administering a therapeutic dose of the composition to the subject.